What the business is
A Belgium-based biotech developing antiviral antibody therapies against coronaviruses using a llama-derived nanobody technology platform.
The bet
Llama-derived antibodies, smaller than human ones, could bind SARS-CoV-2 sites human antibodies can't reach — working as both therapeutic and prophylactic.
Starting capital
Raised a $27M Series A round in July 2020 led by Fund+, with participation from VIB, UCB Ventures, Belgium's federal investment vehicle SFPI-FPIM, V-Bio Ventures and Belgian family offices.
How it started
ExeVir Bio was founded in Belgium by research institute VIB together with UCB Ventures and Fund+, built around a llama-derived antibody platform whose single-domain antibodies had shown in preclinical work that they could neutralize SARS-CoV-2 and bind a unique epitope shared with SARS-CoV-1.
What happened
ExeVir closed a $27M Series A round led by Fund+, with UCB Ventures, VIB, the Belgian government's SFPI-FPIM, V-Bio Ventures and family offices participating; CEO Torsten Mummenbrauer, Fund+ partner Philippe Monteyne, UCB Ventures head Erica Whittaker, VIB's Jérôme Van Biervliet and V-Bio's Katja Rosenkranz joined the board. Mummenbrauer said the funding would let ExeVir 'rapidly advance the development of our lead compound,' VHH72-Fc, into clinical studies by the end of the year, targeting both a COVID-19 therapeutic and a prophylactic use.
What has to be true
The COVID-19 pandemic created urgent global demand for antiviral therapeutics and preventives, giving ExeVir a receptive funding environment.
A structural advantage — nanobodies smaller than human antibodies, reaching otherwise inaccessible viral epitopes — gave investors a specific technical thesis, not a generic pandemic bet.
Backing from VIB, the Belgian institute that helped found the company, and a Belgian government fund signaled domestic institutional confidence alongside private VC money.
Dual use as both a therapeutic and a prophylactic widened the candidate's potential market if clinical trials succeeded.
What can be applied
In a pandemic funding rush, a technical differentiator grounded in prior academic research gave a young biotech a testable reason for investors to back it over a generic 'COVID antibody' pitch.
Aftermath
At the time of the report, ExeVir had just closed its Series A and planned to move VHH72-Fc into clinical studies by the end of 2020; the material does not document later trial results or outcomes.
FOLLOW THE EVIDENCE